Craig-Hallum initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $109 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics’ APG777 Study: A Potential Breakthrough in Atopic Dermatitis Treatment
- Apogee Therapeutics’ New Study on Atopic Dermatitis: What Investors Need to Know
- Apogee Therapeutics’ Promising Update on Long-term APG777 Study for Atopic Dermatitis
- Mizuho Securities Recommends Buy for Apogee Therapeutics Due to Promising APG777 Efficacy in Th2 Inflammatory Diseases
- Apogee Therapeutics initiated with an Outperform at Mizuho